Maikel Mansour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maikel Mansour has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Camilla Macia
Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
14 shared publications - Dominique Ballinger
Department of Medicine Division of Haematology‐Oncology, University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA
14 shared publications - Erica L. Carpenter
Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
14 shared publications - Jacob E. Till
Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
14 shared publications - Melinda Yin
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
14 shared publications - Shivani S. Shah
Department of Neurosurgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
14 shared publications
Latest Publications
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500456
Next-Generation Sequencing of Intraoperatively Acquired Cerebrospinal Fluid and Matched Tumor Tissue in Patients Undergoing Surgical Resection for Glioblastoma
PURPOSE: Because of tumor heterogeneity and sampling error, next-generation sequencing (NGS) of glioblastoma (GBM) tumors may provide an incomplete picture of the somatic mutational landscape. We hypothesized that simultaneous targeted NGS of matched tumor tissue and cerebrospinal fluid (CSF), obtained during craniotomy for resection of GBM, would lead to identification of clinically relevant variants not detected by tissue NGS alone. METHODS: We enrolled 50 patients undergoing resection of newly diagnosed (n = 15) or recurrent (n = 35) GBM. CSF was collected intraoperatively via the subarachnoid space (n = 25) or lateral ventricle (n = 25) and assayed by NGS using a hybrid capture liquid biopsy panel. Matched tumor tissue also underwent large panel hybrid capture NGS testing. RESULTS: CSF samples from 28 of 50 patients (56%) passed quality control metrics. At least one CSF variant was detected in 25 of 28 patients (89%), and 22 of 28 patients had matched tissue sequencing results available. In these 22 patients (primary analysis cohort), the median number of variants detected in CSF was higher than in tissue (3 v 2 variants, respectively; P = .0035), and 15 of 22 patients (68%) had ≥1 CSF variant not detected in matched tissue, including clinically relevant alterations in EGFR , PMS2 , PIK3CA , and TP53 . CONCLUSION: The addition of intraoperatively acquired CSF liquid biopsy to tissue NGS in patients with GBM may improve detection of clinically relevant variants, potentially improving selection of patients for clinical trials.
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500456
Next-Generation Sequencing of Intraoperatively Acquired Cerebrospinal Fluid and Matched Tumor Tissue in Patients Undergoing Surgical Resection for Glioblastoma
PURPOSE: Because of tumor heterogeneity and sampling error, next-generation sequencing (NGS) of glioblastoma (GBM) tumors may provide an incomplete picture of the somatic mutational landscape. We hypothesized that simultaneous targeted NGS of matched tumor tissue and cerebrospinal fluid (CSF), obtained during craniotomy for resection of GBM, would lead to identification of clinically relevant variants not detected by tissue NGS alone. METHODS: We enrolled 50 patients undergoing resection of newly diagnosed (n = 15) or recurrent (n = 35) GBM. CSF was collected intraoperatively via the subarachnoid space (n = 25) or lateral ventricle (n = 25) and assayed by NGS using a hybrid capture liquid biopsy panel. Matched tumor tissue also underwent large panel hybrid capture NGS testing. RESULTS: CSF samples from 28 of 50 patients (56%) passed quality control metrics. At least one CSF variant was detected in 25 of 28 patients (89%), and 22 of 28 patients had matched tissue sequencing results available. In these 22 patients (primary analysis cohort), the median number of variants detected in CSF was higher than in tissue (3 v 2 variants, respectively; P = .0035), and 15 of 22 patients (68%) had ≥1 CSF variant not detected in matched tissue, including clinically relevant alterations in EGFR , PMS2 , PIK3CA , and TP53 . CONCLUSION: The addition of intraoperatively acquired CSF liquid biopsy to tissue NGS in patients with GBM may improve detection of clinically relevant variants, potentially improving selection of patients for clinical trials.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S14 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
Supplemental Figure 1. Patients and assays Supplemental Figure 2. Survival analysis at baseline and post-radiation Supplemental Figure 3. Correlative analysis of all ccfDNA deconvolution subsets with [ccfDNA]. Supplemental Figure 4. Analysis of % neutrophil tissue DNA and pre-operative steroids. Supplemental Figure 5. Correlative analysis of all ccfDNA deconvolution subsets with [citH3]. Supplemental Figure 6. Analysis of % neutrophil tissue DNA and [citH3]. Supplemental Figure 7. Analysis of [citH3], pre-operative steroid dose, and tumor volume. Supplemental Figure 8. Analysis of % neutrophil ccfDNA by steroid exposure. Supplemental Figure 9. Percent neutrophil ccfDNA and [citH3] at time of first post-radiation MRI. Supplemental Figure 10. Analysis of % neutrophil ccfDNA and total [ccfDNA] by steroid exposure. Supplemental Figure 11. Molecular sub-type analysis of Clusters 1 and 2 from plasma ccfDNA differential methylation results. Supplemental Figure 12. Unsupervised clustering of tissue DNA methylation data, differential methylation, and pathway analysis. Supplemental Figure 13. Analysis of Clusters 1 and 2 from tissue DNA differential methylation analysis. Supplemental Figure 14. Analysis of Clusters 1 and 2 from plasma ccfDNA differential methylation results.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S14 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
Supplemental Figure 1. Patients and assays Supplemental Figure 2. Survival analysis at baseline and post-radiation Supplemental Figure 3. Correlative analysis of all ccfDNA deconvolution subsets with [ccfDNA]. Supplemental Figure 4. Analysis of % neutrophil tissue DNA and pre-operative steroids. Supplemental Figure 5. Correlative analysis of all ccfDNA deconvolution subsets with [citH3]. Supplemental Figure 6. Analysis of % neutrophil tissue DNA and [citH3]. Supplemental Figure 7. Analysis of [citH3], pre-operative steroid dose, and tumor volume. Supplemental Figure 8. Analysis of % neutrophil ccfDNA by steroid exposure. Supplemental Figure 9. Percent neutrophil ccfDNA and [citH3] at time of first post-radiation MRI. Supplemental Figure 10. Analysis of % neutrophil ccfDNA and total [ccfDNA] by steroid exposure. Supplemental Figure 11. Molecular sub-type analysis of Clusters 1 and 2 from plasma ccfDNA differential methylation results. Supplemental Figure 12. Unsupervised clustering of tissue DNA methylation data, differential methylation, and pathway analysis. Supplemental Figure 13. Analysis of Clusters 1 and 2 from tissue DNA differential methylation analysis. Supplemental Figure 14. Analysis of Clusters 1 and 2 from plasma ccfDNA differential methylation results.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
List of all methylGSA results for (Gene Ontology,GO, gene sets) with differential methylation comparing patients in cluster 1 vs cluster 2 from unsupervised clustering of the tissue DNA methylation results.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
List of all methylGSA results for (Gene Ontology,GO, gene sets) with differential methylation comparing patients in cluster 1 vs cluster 2 from unsupervised clustering of the tissue DNA methylation results.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
Published reference methylomes used in deconvolution
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
Published reference methylomes used in deconvolution
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
List of all methylGSA results for (Gene Ontology,GO, gene sets) with differential methylation by pre-operative steroid exposure (exposed vs unexposed).
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
List of all methylGSA results for (Gene Ontology,GO, gene sets) with differential methylation by pre-operative steroid exposure (exposed vs unexposed).
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
Representativeness of Study Participants
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
Representativeness of Study Participants
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
List of all methylGSA results for (Gene Ontology,GO, gene sets) with differential methylation for % neutrophil ccfDNA dichotomized at median.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
List of all methylGSA results for (Gene Ontology,GO, gene sets) with differential methylation for % neutrophil ccfDNA dichotomized at median.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
List of all methylGSA results for (Gene Ontology,GO, gene sets) with differential methylation for plasma [citH3] dichotomized at median.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
List of all methylGSA results for (Gene Ontology,GO, gene sets) with differential methylation for plasma [citH3] dichotomized at median.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
List of genes included in bespoke NETosis gene set.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
List of genes included in bespoke NETosis gene set.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
List of all methylGSA results for (Gene Ontology,GO, gene sets) differential methylation comparing cluster 1 vs cluster 2 from unsupervised clustering of the plasma ccfDNA methylation results.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
List of all methylGSA results for (Gene Ontology,GO, gene sets) differential methylation comparing cluster 1 vs cluster 2 from unsupervised clustering of the plasma ccfDNA methylation results.